Neos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on August 11, 2016
02 août 2016 07h00 HE
|
Neos Therapeutics, Inc
DALLAS-FORT WORTH, Texas, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Announces Successful Completion of Bioequivalence Bridging Study for Cotempla XR-ODT™ (Methylphenidate Extended-Release Orally Disintegrating Tablet)
28 juil. 2016 16h05 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, July 28, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics CEO to Present at JMP Securities Life Sciences Conference on June 21, 2016
14 juin 2016 07h00 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 14, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer
31 mai 2016 16h05 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 31, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics CEO to Present at 2016 UBS Healthcare Conference on May 24, 2016
17 mai 2016 07h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial Results
16 mai 2016 06h05 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older
16 mai 2016 06h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR)...
Neos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on May 16, 2016
05 mai 2016 07h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 05, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results
17 mars 2016 07h00 HE
|
Neos Therapeutics, Inc.
Launch of Adzenys XR-ODT in Second Quarter of 2016 Company to Host Conference Call at 8:30am ET Today DALLAS/FORT WORTH, Texas, March 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc....
Neos Therapeutics Announces Date of Fourth Quarter and 2015 Fiscal Year Financial Results
08 mars 2016 07h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, March 08, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...